|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: COMMD2 |
Gene summary for COMMD2 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | COMMD2 | Gene ID | 51122 |
| Gene name | COMM domain containing 2 | |
| Gene Alias | HSPC042 | |
| Cytomap | 3q25.1 | |
| Gene Type | protein-coding | GO ID | GO:0005575 | UniProtAcc | Q86X83 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 51122 | COMMD2 | LZE2T | Human | Esophagus | ESCC | 1.31e-09 | 8.84e-01 | 0.082 |
| 51122 | COMMD2 | LZE3D | Human | Esophagus | HGIN | 2.24e-03 | 8.45e-01 | 0.0668 |
| 51122 | COMMD2 | LZE4T | Human | Esophagus | ESCC | 1.29e-32 | 8.54e-01 | 0.0811 |
| 51122 | COMMD2 | LZE7T | Human | Esophagus | ESCC | 3.37e-13 | 6.56e-01 | 0.0667 |
| 51122 | COMMD2 | LZE8T | Human | Esophagus | ESCC | 1.16e-07 | 3.15e-01 | 0.067 |
| 51122 | COMMD2 | LZE20T | Human | Esophagus | ESCC | 1.81e-10 | 4.36e-01 | 0.0662 |
| 51122 | COMMD2 | LZE22D1 | Human | Esophagus | HGIN | 2.97e-05 | 1.93e-01 | 0.0595 |
| 51122 | COMMD2 | LZE22T | Human | Esophagus | ESCC | 2.01e-12 | 8.30e-01 | 0.068 |
| 51122 | COMMD2 | LZE24T | Human | Esophagus | ESCC | 4.28e-31 | 7.95e-01 | 0.0596 |
| 51122 | COMMD2 | LZE21T | Human | Esophagus | ESCC | 3.85e-08 | 6.94e-01 | 0.0655 |
| 51122 | COMMD2 | LZE6T | Human | Esophagus | ESCC | 2.70e-13 | 8.15e-01 | 0.0845 |
| 51122 | COMMD2 | P1T-E | Human | Esophagus | ESCC | 3.22e-14 | 8.05e-01 | 0.0875 |
| 51122 | COMMD2 | P2T-E | Human | Esophagus | ESCC | 6.39e-106 | 1.87e+00 | 0.1177 |
| 51122 | COMMD2 | P4T-E | Human | Esophagus | ESCC | 1.72e-62 | 1.43e+00 | 0.1323 |
| 51122 | COMMD2 | P5T-E | Human | Esophagus | ESCC | 6.94e-60 | 1.11e+00 | 0.1327 |
| 51122 | COMMD2 | P8T-E | Human | Esophagus | ESCC | 2.25e-75 | 1.25e+00 | 0.0889 |
| 51122 | COMMD2 | P9T-E | Human | Esophagus | ESCC | 1.42e-36 | 7.78e-01 | 0.1131 |
| 51122 | COMMD2 | P10T-E | Human | Esophagus | ESCC | 1.36e-86 | 1.46e+00 | 0.116 |
| 51122 | COMMD2 | P11T-E | Human | Esophagus | ESCC | 2.41e-20 | 7.26e-01 | 0.1426 |
| 51122 | COMMD2 | P12T-E | Human | Esophagus | ESCC | 2.27e-50 | 8.85e-01 | 0.1122 |
| Page: 1 2 3 4 5 6 7 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| COMMD2 | SNV | Missense_Mutation | novel | c.305N>C | p.Leu102Pro | p.L102P | Q86X83 | protein_coding | deleterious(0.01) | probably_damaging(0.915) | TCGA-EW-A6SB-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| COMMD2 | deletion | In_Frame_Del | c.100_102delNNN | p.Phe34del | p.F34del | Q86X83 | protein_coding | TCGA-A8-A09V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD | |||
| COMMD2 | SNV | Missense_Mutation | novel | c.478N>T | p.His160Tyr | p.H160Y | Q86X83 | protein_coding | tolerated(0.09) | benign(0.084) | TCGA-EA-A3HU-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| COMMD2 | SNV | Missense_Mutation | c.517N>T | p.Leu173Phe | p.L173F | Q86X83 | protein_coding | tolerated(0.06) | possibly_damaging(0.626) | TCGA-AA-3710-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| COMMD2 | SNV | Missense_Mutation | c.387G>T | p.Trp129Cys | p.W129C | Q86X83 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-AA-3815-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| COMMD2 | SNV | Missense_Mutation | rs779093793 | c.586N>T | p.Arg196Cys | p.R196C | Q86X83 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AA-A00N-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
| COMMD2 | SNV | Missense_Mutation | c.439G>A | p.Ala147Thr | p.A147T | Q86X83 | protein_coding | tolerated(0.44) | benign(0.003) | TCGA-AA-A010-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Chemotherapy | folinic | CR | |
| COMMD2 | SNV | Missense_Mutation | novel | c.290A>G | p.Lys97Arg | p.K97R | Q86X83 | protein_coding | tolerated(0.25) | benign(0.018) | TCGA-AG-3892-01 | Colorectum | rectum adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| COMMD2 | SNV | Missense_Mutation | rs373377514 | c.49C>T | p.Pro17Ser | p.P17S | Q86X83 | protein_coding | tolerated(0.63) | benign(0.012) | TCGA-AP-A1DK-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| COMMD2 | SNV | Missense_Mutation | novel | c.293N>C | p.Leu98Ser | p.L98S | Q86X83 | protein_coding | tolerated(0.4) | benign(0.081) | TCGA-AX-A1CE-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unspecific | Paclitaxel | SD |
| Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |